Warner Chilcott Prevails Vs. Teva In Sarafem Patent Suit

Law360, New York (August 6, 2004, 12:00 AM EDT) -- A federal district court has upheld the validity of a patent for Irish drug maker Warner Chilcott’s pre-menstrual dysphoric disorder treatment Sarafem, rejecting a challenge by Israeli generics maker Teva Pharmaceuticals.

In a 90-page decision, Chief Judge Sarah Barker of the U.S. District Court for the Southern District of Indiana found in favor of Lilly and Warner Chilcott, and upheld the validity of the Sarafem patent. As a result, injunctive relief is available to Warner Chilcott until the expiration of the patent in May 2008....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.